Conditions: 97.1% · oral semaglutide · QSC.
The failure mode I am trying to avoid is making this decision emotionally.
I have twelve months in view and I would like the plan to survive that long.
How would you structure this, and what thresholds would you set in advance?
97.1 per cent purity with no content figure leaves the milligram number unmeasured. Purity says 97.1 of every 100 units of detected area is oral semaglutide and 2.9 is something else. Content says how many milligrams are in the glass. The two do not constrain each other: a vial can be 97.1 per cent pure and still be under label, because water and counter-ion are part of the gross mass and neither shows up as an impurity peak. If you buy one test, buy the one that changes your arithmetic.
Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
The underlying point is that sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsWorth being precise here: gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
In practice, tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Stated carefully, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
Specifically, mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
Compare purity within a single laboratory on the same method, never across laboratories.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.